Valeo Pharma Inc. Stock price Canadian Securities Exchange

Equities

VPH

CA91915B1085

Pharmaceuticals

Delayed Canadian Securities Exchange 03:57:37 2022-03-28 pm EDT 5-day change 1st Jan Change
0.66 CAD -.--% Intraday chart for Valeo Pharma Inc. +1.54% -10.81%
Sales 2024 * 61M 44.88M Sales 2025 * 75.83M 55.79M Capitalization 15.79M 11.61M
Net income 2024 * -18M -13.24M Net income 2025 * -12M -8.83M EV / Sales 2024 * 1.12 x
Net Debt 2024 * 52.53M 38.65M Net cash position 2025 * - 0 EV / Sales 2025 * 0.21 x
P/E ratio 2024 *
-0.8 x
P/E ratio 2025 *
-1.23 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.77%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 65 03-03-26
Director of Finance/CFO - Nov. 19
Chief Tech/Sci/R&D Officer - 21-05-31
Members of the board TitleAgeSince
Chairman 89 18-07-24
Founder 65 03-03-26
Director/Board Member 65 22-04-26
More insiders
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.16 CAD
Average target price
0.5 CAD
Spread / Average Target
+212.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Valeo Pharma Inc.
  4. Stock Valeo Pharma Inc. - Canadian Securities Exchange